ACTRN12615001189516尚未招募1 期
Breaking up Sitting Time after Stroke (BUST-Stroke): A randomised within-participant cross-over study to determine the metabolic effects of breaking up uninterrupted sitting time in stroke survivors.
niversity of Newcastle0 个研究点目标入组 19 人开始时间: 2015年11月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Stroke survivors who are:
- •*Greater than or equal to 6 months post-stroke with moderate walking disability as defined as
- •*score of =2 on the Functional Ambulation Classification (ie. require the assistance of less than or equal to 1 person to safely walk) AND
- •*walking speed between 0.4 to 0.8m/s
- •*able to toilet independently and
- •*able to stand from sitting from a lounge chair independently or with minimal assistance of less than or equal to 1 person
排除标准
- •*employment in a non-sedentary occupation (ie. non-office based occupation),
- •*self-reported < 4 hours/day sitting
- •*regularly engaged in physical activity (ie. greater than or equal to 150min/week) as assessed by self-report
- •*BMI > 45kg/m2
- •*current smoker
- •*clinically diagnosed with acute/chronic illness or other condition which has known physical activity contraindications or limits their ability to complete the each experimental condition (ie. chronic low back pain aggravated by prolonged sitting)
- •*urinary frequency and or urinary urgency or requiring assistance with toileting (other than to mobilise to the toilet) and
- •*insulin dependent diabetes or who are taking diabetes medication other than metformin.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairmentpatients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairmentMedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002619-14-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.406
进行中（未招募）
1 期
A 24 week study comparing closed triple therapy delivered as FF/UMEC/VI vs open triple therapy delivered as FF/VI + UMEC in COPD patients.EUCTR2015-005212-14-ROGlaxoSmithKline Research & Development Ltd1,311
进行中（未招募）
1 期
A phase IIIB, 24-week randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD) - 200812EUCTR2015-005212-14-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT1,311
进行中（未招募）
1 期
A 24 week study comparing 'closed' triple therapy delivered asFF/UMEC/VI vs 'open' triple therapy delivered as FF/VI + UMEC in COPD patients.in subjects with chronic obstructive pulmonary disease (COPD)MedDRA version: 18.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-005212-14-ESGlaxoSmithKline, S.A.1,020
进行中（未招募）
1 期
A 24 week study comparing closed triple therapy delivered as FF/UMEC/VI vs open triple therapy delivered as FF/VI + UMEC in COPD patients.in subjects with chronic obstructive pulmonary disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-005212-14-FRGlaxoSmithKline Research & Development Ltd1,020